Literature DB >> 22969943

Peritumoral lymphatic microvessel density is related to poor prognosis in lung adenocarcinoma: A retrospective study of 65 cases.

Bi-Cheng Zhang1, Sha Guan, Ya-Fei Zhang, Guo-Qing Yao, Bo Yang, Yong Zhao, Zhi-Guo Rao, Jian-Fei Gao.   

Abstract

Although recent investigations have identified that lymphangiogenesis is associated with regional lymph node metastasis and tumor prognosis in non-small cell lung cancer (NSCLC), peritumoral lymphatic microvessel density (LMVD) and its prognostic significance in lung adenocarcinoma remain unknown. In the present study, we assessed peritumoral LMVD in lung adenocarcinoma and investigated its correlation with patient prognosis. Using immunohistochemistry (SP method), the D2-40-positive peritumoral LMVD count in lung adenocarcinoma was found to be 11.56±10.73, which was higher than intratumoral LMVD (P<0.001), and was found to be associated with lymphatic metastasis (P=0.003) and pTNM staging (P=0.046). Furthermore, a significant difference in the patient overall survival time was demonstrated between tumors with a high peritumoral LMVD and those with a low peritumoral LMVD (P=0.005). Finally, using multivariate analysis, it was determined that peritumoral LMVD, lymphatic metastasis and pTNM staging were independent prognostic factors. In conclusion, the results suggest that D2-40-positive peritumoral LMVD may predict the prognosis of lung adenocarcinoma.

Entities:  

Year:  2012        PMID: 22969943      PMCID: PMC3438604          DOI: 10.3892/etm.2012.470

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  33 in total

1.  Lymphatic microvessel density using D2-40 is associated with nodal metastasis in non-small cell lung cancer.

Authors:  Iwao Takanami
Journal:  Oncol Rep       Date:  2006-02       Impact factor: 3.906

Review 2.  Lymphangiogenesis in development and human disease.

Authors:  Kari Alitalo; Tuomas Tammela; Tatiana V Petrova
Journal:  Nature       Date:  2005-12-15       Impact factor: 49.962

Review 3.  Lymphangiogenesis and expression of specific molecules as lymphatic endothelial cell markers.

Authors:  Seiji Kato; Hiroshi Shimoda; Rui-Cheng Ji; Masahiro Miura
Journal:  Anat Sci Int       Date:  2006-06       Impact factor: 1.741

Review 4.  Molecular pathways for lymphangiogenesis and their role in human disease.

Authors:  Steven A Stacker; Rae H Farnsworth; Tara Karnezis; Ramin Shayan; Darrin P Smith; Karri Paavonen; Natalia Davydova; Carol Caesar; Rachael Inder; Megan E Baldwin; Bradley K McColl; Sally Roufail; Richard A Williams; Richard A Hughes; Kari Alitalo; Marc G Achen
Journal:  Novartis Found Symp       Date:  2007

5.  Lymphangiogenesis correlates with lymph node metastasis, prognosis, and angiogenic phenotype in human non-small cell lung cancer.

Authors:  Ferenc Renyi-Vamos; Jozsef Tovari; Janos Fillinger; Jozsef Timar; Sandor Paku; Istvan Kenessey; Gyula Ostoros; Laszlo Agocs; Ibolya Soltesz; Balazs Dome
Journal:  Clin Cancer Res       Date:  2005-10-15       Impact factor: 12.531

6.  Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis.

Authors:  S J Mandriota; L Jussila; M Jeltsch; A Compagni; D Baetens; R Prevo; S Banerji; J Huarte; R Montesano; D G Jackson; L Orci; K Alitalo; G Christofori; M S Pepper
Journal:  EMBO J       Date:  2001-02-15       Impact factor: 11.598

7.  Lymphatic metastasis in the absence of functional intratumor lymphatics.

Authors:  Timothy P Padera; Ananth Kadambi; Emmanuelle di Tomaso; Carla Mouta Carreira; Edward B Brown; Yves Boucher; Noah C Choi; Douglas Mathisen; John Wain; Eugene J Mark; Lance L Munn; Rakesh K Jain
Journal:  Science       Date:  2002-04-25       Impact factor: 47.728

8.  Intratumoral lymphatics and lymphatic invasion are associated with tumor aggressiveness and poor prognosis in renal cell carcinoma.

Authors:  Akio Horiguchi; Keiichi Ito; Makoto Sumitomo; Fumihiro Kimura; Tomohiko Asano; Masamichi Hayakawa
Journal:  Urology       Date:  2008-02-21       Impact factor: 2.649

Review 9.  First-line treatment in advanced non-small-cell lung cancer: the emerging role of the histologic subtype.

Authors:  Marcello Tiseo; Marco Bartolotti; Francesco Gelsomino; Andrea Ardizzoni
Journal:  Expert Rev Anticancer Ther       Date:  2009-04       Impact factor: 4.512

10.  The clinical significance of lymphangiogenesis and angiogenesis in non-small cell lung cancer patients.

Authors:  Kyuichi Kadota; Cheng-Long Huang; Dage Liu; Masaki Ueno; Yoshio Kushida; Reiji Haba; Hiroyasu Yokomise
Journal:  Eur J Cancer       Date:  2008-04-08       Impact factor: 9.162

View more
  4 in total

1.  Combination of Peri- and Intratumoral Radiomic Features on Baseline CT Scans Predicts Response to Chemotherapy in Lung Adenocarcinoma.

Authors:  Mohammadhadi Khorrami; Monica Khunger; Alexia Zagouras; Pradnya Patil; Rajat Thawani; Kaustav Bera; Prabhakar Rajiah; Pingfu Fu; Vamsidhar Velcheti; Anant Madabhushi
Journal:  Radiol Artif Intell       Date:  2019-03-20

2.  The overexpression of PDGF-BB and its receptor is correlated with lymphatic metastasis in patients with non-small cell lung cancer.

Authors:  Ning Zhang; Huixian Hu; Yongqiang Fu; Fang He; Lili Wang; Shunhong Zhuang; Mingxing Ding
Journal:  Int J Clin Exp Pathol       Date:  2018-12-01

3.  Distinguishing granulomas from adenocarcinomas by integrating stable and discriminating radiomic features on non-contrast computed tomography scans.

Authors:  Mohammadhadi Khorrami; Kaustav Bera; Rajat Thawani; Prabhakar Rajiah; Amit Gupta; Pingfu Fu; Philip Linden; Nathan Pennell; Frank Jacono; Robert C Gilkeson; Vamsidhar Velcheti; Anant Madabhushi
Journal:  Eur J Cancer       Date:  2021-03-17       Impact factor: 9.162

4.  Lymphatic vessel density as a prognostic indicator in Asian NSCLC patients: a meta-analysis.

Authors:  Shuanglan Xu; Jiao Yang; Shuangyan Xu; Yun Zhu; Chunfang Zhang; Liqiong Liu; Hao Liu; Yunlong Dong; Zhaowei Teng; Xiqian Xing
Journal:  BMC Pulm Med       Date:  2018-08-06       Impact factor: 3.317

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.